
    
      A Randomised Double-Blind Placebo-controlled Multicentre Phase I Study to Assess the
      Biological Activity of AZD8931 in Patients with Early Breast Cancer who are Ineligible for
      Treatment with trastuzumab as defined by IHC status
    
  